PROFILO GENERALE DELLA FLUVOXAMINA

Translated title of the contribution: General profile of fluvoxamine

D. De Maio, A. Bertolino, M. Casacchia, G. Ceccarelli, U. Ecari, C. Giove, A. Marino, A. A. Rizzoli, F. Savoldi

Research output: Contribution to journalArticle

Abstract

A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

Original languageItalian
Pages (from-to)626-650
Number of pages25
JournalRivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali
Volume115
Issue number4
Publication statusPublished - 1991

Fingerprint

Fluvoxamine
Panic Disorder
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Anxiety Disorders
Synaptic Transmission
Antidepressive Agents
Substance-Related Disorders
Consensus
Safety
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

De Maio, D., Bertolino, A., Casacchia, M., Ceccarelli, G., Ecari, U., Giove, C., ... Savoldi, F. (1991). PROFILO GENERALE DELLA FLUVOXAMINA. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, 115(4), 626-650.

PROFILO GENERALE DELLA FLUVOXAMINA. / De Maio, D.; Bertolino, A.; Casacchia, M.; Ceccarelli, G.; Ecari, U.; Giove, C.; Marino, A.; Rizzoli, A. A.; Savoldi, F.

In: Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, Vol. 115, No. 4, 1991, p. 626-650.

Research output: Contribution to journalArticle

De Maio, D, Bertolino, A, Casacchia, M, Ceccarelli, G, Ecari, U, Giove, C, Marino, A, Rizzoli, AA & Savoldi, F 1991, 'PROFILO GENERALE DELLA FLUVOXAMINA', Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali, vol. 115, no. 4, pp. 626-650.
De Maio D, Bertolino A, Casacchia M, Ceccarelli G, Ecari U, Giove C et al. PROFILO GENERALE DELLA FLUVOXAMINA. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali. 1991;115(4):626-650.
De Maio, D. ; Bertolino, A. ; Casacchia, M. ; Ceccarelli, G. ; Ecari, U. ; Giove, C. ; Marino, A. ; Rizzoli, A. A. ; Savoldi, F. / PROFILO GENERALE DELLA FLUVOXAMINA. In: Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali. 1991 ; Vol. 115, No. 4. pp. 626-650.
@article{67e7d63ff512494b9c063346fda5cfcb,
title = "PROFILO GENERALE DELLA FLUVOXAMINA",
abstract = "A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.",
author = "{De Maio}, D. and A. Bertolino and M. Casacchia and G. Ceccarelli and U. Ecari and C. Giove and A. Marino and Rizzoli, {A. A.} and F. Savoldi",
year = "1991",
language = "Italian",
volume = "115",
pages = "626--650",
journal = "Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali",
issn = "0035-7057",
number = "4",

}

TY - JOUR

T1 - PROFILO GENERALE DELLA FLUVOXAMINA

AU - De Maio, D.

AU - Bertolino, A.

AU - Casacchia, M.

AU - Ceccarelli, G.

AU - Ecari, U.

AU - Giove, C.

AU - Marino, A.

AU - Rizzoli, A. A.

AU - Savoldi, F.

PY - 1991

Y1 - 1991

N2 - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

AB - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

UR - http://www.scopus.com/inward/record.url?scp=0025999996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999996&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0025999996

VL - 115

SP - 626

EP - 650

JO - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali

JF - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali

SN - 0035-7057

IS - 4

ER -